Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Arjo

BATS-CHIXE:ARJOBS
Snowflake Description

Reasonable growth potential with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ARJOBS
BATS-CHIXE
SEK14B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
ARJOBS Share Price and Events
7 Day Returns
3.3%
BATS-CHIXE:ARJOBS
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
45.4%
BATS-CHIXE:ARJOBS
-0.3%
GB Medical Equipment
-23.6%
GB Market
ARJOBS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arjo (ARJOBS) 3.3% -0.3% 10.6% 45.4% - -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • ARJOBS outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • ARJOBS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
ARJOBS
Industry
5yr Volatility vs Market

Value

 Is Arjo undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Arjo to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Arjo.

BATS-CHIXE:ARJOBS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.4%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:ARJOBS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 22%) (48.6%))
1.076
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.08
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.076 * 5.44%)
6.38%

Discounted Cash Flow Calculation for BATS-CHIXE:ARJOBS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Arjo is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:ARJOBS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 6.38%)
2020 617.50 Analyst x2 580.44
2021 767.50 Analyst x2 678.14
2022 869.00 Analyst x2 721.74
2023 939.84 Est @ 8.15% 733.73
2024 994.97 Est @ 5.87% 730.15
2025 1,037.41 Est @ 4.26% 715.60
2026 1,070.03 Est @ 3.14% 693.80
2027 1,095.28 Est @ 2.36% 667.55
2028 1,115.12 Est @ 1.81% 638.85
2029 1,131.03 Est @ 1.43% 609.08
Present value of next 10 years cash flows SEK6,769.00
BATS-CHIXE:ARJOBS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK1,131.03 × (1 + 0.53%) ÷ (6.38% – 0.53%)
SEK19,420.14
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK19,420.14 ÷ (1 + 6.38%)10
SEK10,458.14
BATS-CHIXE:ARJOBS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK6,769.00 + SEK10,458.14
SEK17,227.14
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK17,227.14 / 272.37
SEK63.25
BATS-CHIXE:ARJOBS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:ARJOBS represents 0.975x of OM:ARJO B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.975x
Value per Share
(Listing Adjusted, SEK)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 63.25 x 0.975
SEK61.67
Value per share (SEK) From above. SEK61.67
Current discount Discount to share price of SEK50.70
= -1 x (SEK50.70 - SEK61.67) / SEK61.67
17.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Arjo is available for.
Intrinsic value
18%
Share price is SEK50.7 vs Future cash flow value of SEK61.67
Current Discount Checks
For Arjo to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Arjo's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Arjo's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arjo's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arjo's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:ARJOBS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK1.48
OM:ARJO B Share Price ** OM (2020-04-06) in SEK SEK52
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arjo.

BATS-CHIXE:ARJOBS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ARJO B Share Price ÷ EPS (both in SEK)

= 52 ÷ 1.48

35.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arjo is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Arjo is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Arjo's expected growth come at a high price?
Raw Data
BATS-CHIXE:ARJOBS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 35.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
21.3%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:ARJOBS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 35.14x ÷ 21.3%

1.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arjo is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Arjo's assets?
Raw Data
BATS-CHIXE:ARJOBS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK21.71
OM:ARJO B Share Price * OM (2020-04-06) in SEK SEK52
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:ARJOBS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ARJO B Share Price ÷ Book Value per Share (both in SEK)

= 52 ÷ 21.71

2.39x

* Primary Listing of Arjo.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arjo is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Arjo's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Arjo has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arjo expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arjo expected to grow at an attractive rate?
  • Arjo's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Arjo's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Arjo's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:ARJOBS Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:ARJOBS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 21.3%
BATS-CHIXE:ARJOBS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 4.3%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:ARJOBS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:ARJOBS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 10,174 1,624 781 3
2021-12-31 9,776 1,492 684 3
2020-12-31 9,378 1,327 537 3
2020-04-07
BATS-CHIXE:ARJOBS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 8,925 1,252 403
2019-09-30 8,768 1,148 341
2019-06-30 8,608 969 354
2019-03-31 8,397 903 346
2018-12-31 8,217 991 296
2018-09-30 7,978 832 131
2018-06-30 7,792 754 3
2018-03-31 7,700 687 4
2017-12-31 7,688 572 118
2017-09-30 7,794 593 266

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arjo's earnings are expected to grow significantly at over 20% yearly.
  • Arjo's revenue is expected to grow by 4.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:ARJOBS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Arjo Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ARJOBS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 2.87 3.20 2.68 3.00
2021-12-31 2.51 2.76 2.28 3.00
2020-12-31 1.97 2.20 1.74 3.00
2020-04-07
BATS-CHIXE:ARJOBS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 1.48
2019-09-30 1.25
2019-06-30 1.30
2019-03-31 1.27
2018-12-31 1.09
2018-09-30 0.48
2018-06-30 0.01
2018-03-31 0.01
2017-12-31 0.43
2017-09-30 0.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Arjo is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Arjo's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arjo has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arjo performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arjo's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arjo's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Arjo's 1-year earnings growth exceeds its 5-year average (36.1% vs -14%)
  • Arjo's earnings growth has exceeded the GB Medical Equipment industry average in the past year (36.1% vs -9.5%).
Earnings and Revenue History
Arjo's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arjo Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ARJOBS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 8,925.00 403.00 3,020.00 139.00
2019-09-30 8,768.00 341.00 3,023.00 130.00
2019-06-30 8,608.00 354.00 2,990.00 132.00
2019-03-31 8,397.00 346.00 2,908.00 152.00
2018-12-31 8,217.00 296.00 2,876.00 141.00
2018-09-30 7,978.00 131.00 2,906.00 150.00
2018-06-30 7,792.00 3.00 2,832.00 146.00
2018-03-31 7,700.00 4.00 2,836.00 125.00
2017-12-31 7,688.00 118.00 2,707.00 134.00
2017-09-30 7,794.00 266.00 2,635.00 136.00
2016-12-31 7,808.00 490.00 2,408.00 133.00
2015-12-31 8,115.00 307.00 2,614.00 118.00
2014-12-31 7,568.00 619.00 2,359.00 116.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Arjo has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Arjo used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Arjo has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Arjo's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arjo has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arjo's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arjo's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arjo's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Arjo's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arjo's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arjo Company Filings, last reported 3 months ago.

BATS-CHIXE:ARJOBS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 5,914.00 5,506.00 662.00
2019-09-30 5,980.00 5,491.00 604.00
2019-06-30 5,723.00 5,881.00 917.00
2019-03-31 5,804.00 5,217.00 506.00
2018-12-31 5,427.00 5,647.00 961.00
2018-09-30 5,396.00 5,424.00 623.00
2018-06-30 5,378.00 5,528.00 776.00
2018-03-31 5,332.00 5,557.00 999.00
2017-12-31 5,074.00 5,282.00 672.00
2017-09-30 4,006.00 6,649.00 407.00
2016-12-31 10,658.00 1,737.00 1,446.00
2015-12-31 10,227.00 1,741.00 808.00
2014-12-31 10,602.00 1,942.00 1,369.00
  • Arjo's level of debt (93.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (18.3% vs 93.1% today).
  • Debt is well covered by operating cash flow (22.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5.8x coverage).
X
Financial health checks
We assess Arjo's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arjo has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arjo's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.25%
Current annual income from Arjo dividends. Estimated to be 1.66% next year.
If you bought SEK2,000 of Arjo shares you are expected to receive SEK25 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Arjo's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Arjo's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:ARJOBS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:ARJOBS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 1.00 3.00
2021-12-31 0.87 3.00
2020-12-31 0.72 3.00
2020-04-07
BATS-CHIXE:ARJOBS Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2020-04-03 0.650 1.305
2020-02-04 0.650 1.285
2019-03-27 0.550 1.377
2018-03-26 0.500 1.664

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arjo is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Arjo is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Arjo's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Arjo's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3x coverage).
X
Income/ dividend checks
We assess Arjo's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arjo afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arjo has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arjo's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joacim Lindoff
AGE 46
TENURE AS CEO 3.3 years
CEO Bio

Mr. Joacim Lindoff, M.Sc. (Economics), has been the Chief Executive Officer and President at Arjo AB (publ). since 2017. He was President of Patient & Post-Acute Care at Getinge AB and wasa aslo its Acting Chief Executive Officer and Acting President since August 22, 2016 until March 27, 2017. Mr. Lindoff served as the President of Surgical Workflows at Getinge AB since January 1, 2016 until August 22, 2016 and served as its Executive Vice President of The Infection Control Business Area since January 2015 until January 1, 2016. He is Owner of HÖÖRS ANTENN OCH ELEKTRONIKSERVICE. Mr. Lindoff has been at the Getinge Group since 1999 and has held a number of senior positions in Infection Control, both in Sweden and internationally. He has been a Director at Arjo AB (publ) since 2017. He has extensive experience in the industry. He served as the President Sales & Service Europe/International at Infection Control. He served as a Director Arjo Hospital Equipment AB since 2007 until 2015. He holds a B.Sc. in Economics.

CEO Compensation
  • Insufficient data for Joacim to compare compensation growth.
  • Insufficient data for Joacim to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Arjo management team in years:

3.3
Average Tenure
43
Average Age
  • The tenure for the Arjo management team is about average.
Management Team

Joacim Lindoff

TITLE
CEO, President & Director
AGE
46
TENURE
3.3 yrs

Daniel Fäldt

TITLE
Chief Financial Officer
AGE
43
TENURE
0.1 yrs

Mikael Persson

TITLE
Executive Vice President of Product Development
AGE
52
TENURE
3.3 yrs

Saloni Deva

TITLE
Vice President of Investor Relations & Corporate Communications

Ingrid Carlsson

TITLE
Executive VP of Legal & Business Compliance and Board Secretary
AGE
43
TENURE
0.3 yrs

Kornelia Rasmussen

TITLE
Executive Vice President of Marketing Communication & Public Relations
AGE
42

Paul Lyon

TITLE
President Global Sales & Service
AGE
57

Marion Gullstrand

TITLE
Executive Vice President of Human Resources & CSR
AGE
62
TENURE
3.3 yrs

Katarzyna Bobrow

TITLE
Executive Vice President of Quality & Regulatory Compliance
AGE
39
TENURE
3.3 yrs

Christian Stentoft

TITLE
Executive VP & Chief Strategy Officer
AGE
35
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Arjo board of directors in years:

3.3
Average Tenure
58.5
Average Age
  • The tenure for the Arjo board of directors is about average.
Board of Directors

Johan Malmquist

TITLE
Chairman of the Board
COMPENSATION
SEK1M
AGE
58
TENURE
3.3 yrs

Joacim Lindoff

TITLE
CEO, President & Director
AGE
46
TENURE
3.3 yrs

Carl Bennet

TITLE
Vice Chairman
COMPENSATION
SEK667K
AGE
68
TENURE
2.3 yrs

Ulf Grunander

TITLE
Director
COMPENSATION
SEK815K
AGE
65
TENURE
3.3 yrs

Eva Elmstedt

TITLE
Independent Director
COMPENSATION
SEK695K
AGE
59
TENURE
2.7 yrs

Ingrid Hultgren

TITLE
Employee Representative Director
AGE
61
TENURE
3.3 yrs

Carola Lemne

TITLE
Independent Director
COMPENSATION
SEK695K
AGE
61
TENURE
3.3 yrs

Sten Börjesson

TITLE
Employee Representative Director
AGE
52
TENURE
3.3 yrs

Dan Frohm

TITLE
Director
AGE
38
TENURE
0.9 yrs

Kajsa Haraldsson

TITLE
Deputy Board Member
AGE
37
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Arjo individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
02. Mar 20 Buy Mikael Persson Individual 02. Mar 20 02. Mar 20 4,500 SEK50.00 SEK225,000
29. Jul 19 Buy Joacim Lindoff Individual 29. Jul 19 29. Jul 19 13,160 SEK37.72 SEK496,395
21. May 19 Buy Eva Elmstedt Individual 21. May 19 21. May 19 9,000 SEK38.49 SEK346,410
X
Management checks
We assess Arjo's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arjo has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, prevention of pressure ulcers, prevention of deep vein thrombosis, and for obstetric and cardiac diagnostics. It also provides services, such as training in connection with product sales. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmo, Sweden.

Details
Name: Arjo AB (publ)
ARJOBS
Exchange: BATS-CHIXE
Founded: 1957
SEK13,795,518,872
272,369,573
Website: http://www.arjo.com
Address: Arjo AB (publ)
Hans Michelsensgatan 10,
Malmö,
Skåne County, 211 20,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ARJO B Class B Shares OMX Nordic Exchange Stockholm SE SEK 12. Dec 2017
OTCPK ARRJ.F Class B Shares Pink Sheets LLC US USD 12. Dec 2017
DB A39 Class B Shares Deutsche Boerse AG DE EUR 12. Dec 2017
LSE 0HQ8 Class B Shares London Stock Exchange GB SEK 12. Dec 2017
BATS-CHIXE ARJOBS Class B Shares BATS 'Chi-X Europe' GB SEK 12. Dec 2017
Number of employees
Current staff
Staff numbers
6,141
Arjo employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 20:10
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/02/11
Last earnings filing: 2020/04/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.